Navigation Links
Hepatitis B Vaccine - Comprehensive Patent Search
Date:8/4/2011

/p>

Pipeline Developer is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Eliminate unnecessary risk with the industry benchmark in comprehensive patent information.

Imagine having your own team of pharmaceutical patent experts, at a fraction of the cost and without the wait. Used by the world's leading generic pharmaceutical companies and legal teams, Pipeline Developer minimises the risk of wasted developments or legal action, by providing you with nothing less than the very best in comprehensive patent information. Searched and analysed by highly trained, dedicated staff using sophisticated searching techniques, Pipeline Developer delivers results you can rely on. And that means your staff can concentrate on how the patent landscape affects your business, rather than trying to source reliable patent information.

To order this report:

Drug and Medication Industry: Hepatitis B Vaccine - Comprehensive patent search

Drug and Medication Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Drug in New Hepatitis C Clinical Trial
3. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
6. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
7. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
8. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
9. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
10. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
11. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 Reportlinker.com announces ... available in its catalogue:   ... for Optical Coherence Tomography (OCT) ... STUDY OBJECTIVES   ... to offer synopsis of the current and ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D ... results from the global Phase 3 PROMISE study ... simeprevir (TMC435) led to sustained virologic response 12 ... 79 percent of treatment-experienced genotype 1 chronic hepatitis ... all stages of liver fibrosis, when administered once ...
(Date:5/21/2013)... , May 21, 2013 U.S. spending on ... complex diseases such as cancer, multiple sclerosis and rheumatoid ... the end of 2015, according to a forecast released ... (Logo: http://photos.prnewswire.com/prnh/20080827/EXPRESSSCRIPTSLOGO ) "As we ... and health plans to act so they can continue ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 2U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 3U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 4U.S. Spending on Specialty Medications Likely to Increase 67 Percent Through 2015 5
... May 4 Roche Public Affairs Director Stacy Quinn ... Star by the Healthcare Businesswomen,s Association (HBA) at the organization,s annual awards luncheon ... , , ... for detail and has earned the appreciation and respect of the management team, ...
... In conjunction with DURECT Corporation,s (Nasdaq: DRRX ) first quarter 2010 ... will be broadcast live over the internet on Monday, May 10, 2010 ... , , ... , , ...
Cached Medicine Technology:Roche's Quinn Honored as 2010 HBA Rising Star 2Roche's Quinn Honored as 2010 HBA Rising Star 3DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call 2
(Date:5/21/2013)... Daily Gossip Magazine published well-documented articles that are meant to ... on the latest weight loss methods by publishing weekly in-depth ... review of Kyle Leon’s Customized Fat Loss Plan ... lose weight or stay in shape with the minimum effort. ... by a popular fitness trainer, Kyle Leon, who has made ...
(Date:5/21/2013)... York (PRWEB) May 21, 2013 Parker Waichman ... of victims injured by defective medical devices, is offering remarks ... case of the Estate of Fred E. Taylor v. Intuitive ... Orchard). A May 21, 2013, Bloomberg report noted ... acted like a “car dealership” in how it deployed its ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
(Date:5/21/2013)... One-year results from SOURCE XT one of the ... reported today at EuroPCR 2013 show good clinical ... device success for all access approaches, valve sizes and ... up 2688 consecutively enrolled patients (mean age 81.5 years) ... 93 centres in 17 countries between July 2010 and ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
Breaking Medicine News(10 mins):Health News:Customized Fat Loss Plan Review and Diet Secrets Revealed By Daily Gossip Magazine 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 2Health News:Da Vinci Robotic Surgery Lawsuit: Parker Waichman LLP Reacts to Plaintiff’s Attorney’s Closing Argument in Which He Describes Intuitive Surgical as a Car Dealership 3Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3
... Based on finding of a recent study researchers say ... day is an effective preventive // measure for people ... anti-epileptic drug. Studies have also shown its success in ... neuralgia, and migraine headache. Since gabapentin often reduces migraines ...
... study reports that kids with asthma are more likely to ... moving or family relationships. // ,60 children who had ... had a history of chronic stress. Over 18 months, kids ... flow tests, which measured their breathing strength. Both kids and ...
... do much to relieve knee pain associated with osteoarthritis, ... studies comparing the drugs to placebos. ,The ... and around 3,000 received placebos. The average age of ... been experiencing symptoms for about eight years. Since long-term ...
... fatigue but can also be dangerous. In some cases ... hours can cause deep-vein thrombosis, a potentially serious condition ... pelvic veins. , ,The risk is greatest for ... cardiovascular disease, cancer and blood-clotting disorders, according to the ...
... could lead to an enlarged heart by early adulthood, ... .// ,Researchers followed 467 children for almost ... participants at childhood with data obtained at young adulthood. ... size. Participants who had the highest BMI levels in ...
... who take high doses of steroids are more than twice ... not, say researchers based on findings of a recent study. ... the skin, lungs, joints, digestive tract, such as asthma, inflammatory ... health records of 68,781 people who used steroids between 1993 ...
Cached Medicine News:
Sensitive Eyes drops keep soft contact lenses moist....
Lens Plus Sterile Saline Solution...
... Renu Multiplus No Rub formula is the ... today. All steps in one bottle without ... stores soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Sensitive Eyes sterile saline spray is the preservative-free aerosol saline solution for people with eyes sensitive to preservatives. Used for rinsing soft contact lenses after cleaning or thermal or...
Medicine Products: